SEC Company Response from Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Jun 24, 2019
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: June 24, 2019 · CIK: 0001649989 · Accession: 0001144204-19-032076
AI Filing Summary & Sentiment
File numbers found in text: 333-231922
Letter
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
June 24, 2019
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
RE: Outlook Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-231922
Acceleration Request
Requested Date: June 26,
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on June 26, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Marianne Sarrazin of Cooley LLP at (415) 693-2157 or Pia Kaur of Cooley LLP, at (415) 693-2135.
Very truly
yours,
Outlook Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
June 24, 2019
Via
Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
RE: Outlook Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-231922
Acceleration Request
Requested Date: June 26,
2019
Requested Time: 5:00 P.M.
Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities
and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration
Statement”) to become effective on June 26, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been
declared effective, please orally confirm that event with Marianne Sarrazin of Cooley LLP at (415) 693-2157 or Pia Kaur of Cooley
LLP, at (415) 693-2135.
Very truly
yours,
Outlook Therapeutics, Inc.
By:
/s/ Lawrence A. Kenyon
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
cc:
Yvan-Claude Pierre, Cooley LLP
Marianne Sarrazin, Cooley LLP
Pia Kaur, Cooley LLP
T: 609.619.3990 | W: www.outlooktherapeutics.com | E: info@outlooktherapeutics.com